Peter Jezzard
PhD, FInstP, CPhys
Herbert Dunhill Professor of Neuroimaging
- FMRIB/WIN Physics Group
Magnetic Resonance Imaging Physics and Methods Development
My group develops novel physiological MRI methods for the study of healthy and diseased brain.
I am particularly interested in techniques for mapping the macroscopic and microscopic neurovasculature. I collaborate closely with various clinical groups on the development of rapid imaging approaches to aid in the diagnosis and treatment of acute stroke and small vessel disease. A second thread of research aims to advance ultra-high field imaging, utilizing our 7-tesla scanner. This research combines novel imaging hardware, including parallel RF transmission, with state-of-the-art acquisition techniques. Finally, I also work with the Department of Psychiatry on the development of spectroscopic measurement of neurotransmitters.
I am an active member of University College and hold leadership roles in several imaging centres within Oxford (see links to left). In the broader scientific community, I have been active in the International Society for Magnetic Resonance in Medicine in a range of capacities, and am the Editor-in-Chief of the Society journal Magnetic Resonance in Medicine from January 2020.
Recent publications
-
Code review facility in Magnetic Resonance in Medicine.
Malik S. et al, (2024), Magn Reson Med
-
Post-hospitalisation COVID-19 cognitive deficits at one year are global and associated with elevated brain injury markers and grey matter volume reduction.
Wood GK. et al, (2024), Nat Med
-
Improved visualization of intracranial distal arteries with multiple 2D slice dynamic ASL-MRA and super-resolution convolutional neural network.
Suzuki Y. et al, (2024), Magn Reson Med
-
Brain-charting autism and attention deficit hyperactivity disorder reveals distinct and overlapping neurobiology.
Bedford SA. et al, (2024), Biol Psychiatry
-
Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people.
Taylor K. et al, (2024), Lancet Diabetes Endocrinol, 12, 558 - 568